Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity.

Journal: Nature communications
Published Date:

Abstract

In systemic light chain amyloidosis (AL), pathogenic monoclonal immunoglobulin light chains (LC) form toxic aggregates and amyloid fibrils in target organs. Prompt diagnosis is crucial to avoid permanent organ damage, but delayed diagnosis is common because symptoms usually appear only after strong organ involvement. Here we present LICTOR, a machine learning approach predicting LC toxicity in AL, based on the distribution of somatic mutations acquired during clonal selection. LICTOR achieves a specificity and a sensitivity of 0.82 and 0.76, respectively, with an area under the receiver operating characteristic curve (AUC) of 0.87. Tested on an independent set of 12 LCs sequences with known clinical phenotypes, LICTOR achieves a prediction accuracy of 83%. Furthermore, we are able to abolish the toxic phenotype of an LC by in silico reverting two germline-specific somatic mutations identified by LICTOR, and by experimentally assessing the loss of in vivo toxicity in a Caenorhabditis elegans model. Therefore, LICTOR represents a promising strategy for AL diagnosis and reducing high mortality rates in AL.

Authors

  • Maura Garofalo
    Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Luca Piccoli
    Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Margherita Romeo
    Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Maria Monica Barzago
    Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Sara Ravasio
    Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Mathilde Foglierini
    Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Milos Matkovic
    Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Jacopo Sgrignani
    Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Raoul De Gasparo
    Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Marco Prunotto
    Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
  • Luca Varani
    Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Luisa Diomede
    Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
  • Olivier Michielin
    Molecular Modeling Group, SIB Swiss Institute of Bioinformatics, University of Lausanne, Quartier UNIL-Sorge, Bâtiment Amphipôle, Lausanne, Switzerland.
  • Antonio Lanzavecchia
    Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Andrea Cavalli
    1] CompuNet, Istituto Italiano di Tecnologia, via Morego 30, 16163 Genova, Italy [2] Department of Pharmacy and Biotechnology, University of Bologna, via Belmeloro 6, 40126 Bologna, Italy.